What is prostate cancer?
Prostate cancer occurs when cells in the prostate gland grow and
divide in an abnormal way. Prostate cancer can be early (localised)
where cancer cells have grown but not spread, locally advanced where
cancers has spread to parts of the body close to the prostate or
metastatic where the cancer has spread to distant parts of the body.
You can access further information about prostate cancer, including
risk factors, symptoms, diagnosis and treatment from
Cancer
Council Victoria. You can also
call
our trusted cancer nurses on 13 11 20 for support and to learn about
our range of services for people affected by cancer.
The Victorian Cancer Registry also operates an interactive web
portal,
Data
Explorer, which provides more trends and statistics than published
here.
How common is prostate cancer?
In 2023, 6378 Victorian males were diagnosed with prostate cancer.
Currently, prostate cancer is diagnosed at a rate of 159 per 100,000
males. The median age at diagnosis of prostate cancer is 69 years
(Figure 1 & 2). Accounting for 16.2% of all cancers diagnosed and
7.1% of all cancer-related deaths in 2023, prostate cancer was the most
commonly diagnosed cancer and the 2nd most common cause of
cancer-related deaths in Victorian males in 2023.
Trends in prostate cancer over time
Figure 3a shows for males between 2014 to 2023 the age standardised
incidence rate of prostate cancer increased by an average of 2.4% per
year.
Prostate cancer morphology
Figure 4 provides a summary of the different types of cells
(morphology) which have caused prostate cancer among all cases. Most
prostate cancer tumours, 93.7%, present as acinar carcinoma tumours.
Geographical variance in prostate cancer by local government
area
Figure 5 demonstrates variation in age-standardised incidence rates
of prostate cancer, by local government areas. Darker shading indicates
areas with higher rates of prostate cancer.
Prostate cancer in people born overseas
Figure 5 shows the age standardised incidence rates of invasive
prostate cancer in Australian-born Victorian males compared to other
major migrant groups, over the five-year period 2018 to 2022. The
highest age standardised incidence rate of 177.3 was observed in those
born in the North America region and lowest rate of 75 was observed in
people born in the North-East Asia region.
Prostate cancer distribution by stage at diagnosis
Figure 6 shows the distribution of prostate cancer using the
International Society of Urological Pathology (ISUP) Grade Group in
2023. ISUP grade groups categorise prostate cancer at diagnosis
according to five grades from least aggressive (Grade 1) to most
aggressive (Grade 5). These groups help clinicians decide how to manage
the cancer. * Grade group 1 (Gleason 6 or less) indicates that the
cancer is low risk; the cancer is slow growing and not aggressive. *
Grade group 2-3 (Gleason score 7) indicates that the cancer is
intermediate risk; the cancer is likely to grow faster and be mildly to
moderately aggressive. * Grade group 4-5 (Gleason score 8-10) indicates
that the cancer is high risk; the cancer is likely to grow quickly and
be more aggressive.
Among males, ISUP 2 accounted for the largest proportion (29.6%) of new
diagnoses and Metastatic (N1/M1) for the lowest proportion (5.3%) of new
prostate cancer diagnoses.
Prostate cancer five-year relative survival
Figure 7 shows the change in 5-year survival for prostate cancer, and
the 5-year survival trend for all cancers over the same time period. It
demonstrates that five-year relative survival has increased for invasive
prostate cancer between 1983-1987 and 2018-2022 from 53% to 95%.